GTM Playbook for CDMOs: ICP, Signals, Conferences, and Cadence

A CDMO is not selling a generic service into a generic biotech; it is selling manufacturing capacity and process expertise for a specific modality, at a specific scale, against a client timeline that is usually set by a clinical trial or a regulatory milestone rather than by the CDMO itself. That reality should shape the ICP, the signals worth tracking, conference strategy, and cadence differently from a generic life science services playbook.

How the CDMO ICP differs

The two-layer model in building an ICP as a CRO or CDMO applies, but for a CDMO specifically, a few attributes function closer to hard gates than soft preferences:

• Modality, as a near-hard gate. Small molecule, biologics, and cell and gene therapy manufacturing require genuinely different facilities and expertise. A CDMO's ICP should filter on modality before anything else, since a company outside your modality is essentially never a fit, regardless of how strong its other signals look.
• Manufacturing scale and scope. Process development work, clinical-scale manufacturing, and commercial-scale manufacturing are different sales motions with different buyers and different lead times. A CDMO focused on early process development has a different sweet spot than one built for commercial-scale launch support, even within the same modality.
• Buyer function: CMC and manufacturing leadership. Chemistry, manufacturing, and controls (CMC) and manufacturing operations leadership typically own or strongly influence CDMO selection, with quality as a close secondary stakeholder, especially as a program approaches commercial scale.

Which signals matter most for a CDMO

For a CDMO, the facilities, clinical and regulatory, and hiring categories carry disproportionate weight. See the GTM signals glossary for the full catalog:

• Phase transition, especially Phase 2 to Phase 3. This is often the point where a sponsor moves from small-batch process development toward the larger-scale manufacturing that frequently triggers an outside CDMO evaluation for the first time, or a re-evaluation of an existing one.
• FDA approval. Directly creates a commercial-scale manufacturing need, across production, quality, and supply chain, that is one of the highest-value triggers on this list for a commercial-stage CDMO.
• Fast Track and Breakthrough Therapy designations, and Priority Review. All three tend to compress a client's development and commercialization timeline, which increases the value of engaging early given how long manufacturing capacity and tech transfer lead times run.
• New facility or facility expansion, at the client or at a competitor. A client building or expanding its own facility is a signal worth investigating rather than reacting to automatically; see the FAQ below on reading it correctly.
• CMC hiring and executive hiring into manufacturing or quality leadership. Both often precede an active vendor search, since a new CMC or manufacturing leader typically re-evaluates existing vendor relationships as part of settling into the role.
• Funding rounds and milestone payments. Useful context for whether a client can afford to fund a manufacturing scale-up; a phase transition or an approaching regulatory milestone is the more direct trigger, with funding as the backdrop that says the money is there.
• M&A events. Read with care: an acquisition can consolidate manufacturing onto a single vendor (a risk to an existing relationship) or open a reshuffle of vendor relationships across the combined company (an opportunity). Treat it as a reason to re-check the account, not a signal with a fixed direction.

Conference strategy for a CDMO

For a CDMO, manufacturing- and modality-specific shows generally outperform broad biotech shows for direct pipeline. See the full US life science conference calendar for timing and detail:

• DCAT Week, CPHI, and ISPE are close to home turf for a CDMO: sourcing, supply chain, and manufacturing-operations audiences specifically, with DCAT Week in particular built around pre-scheduled one-on-one meetings rather than a general show floor.
• Modality-specific manufacturing shows, Biotech Week Boston, BPI West, and Phacilitate Advanced Therapies Week for cell and gene therapy manufacturing specifically, reach the exact modality and scale-stage audience a focused CDMO needs.
• INTERPHEX reaches a broader pharma and biotech manufacturing-technology audience, useful for a CDMO with wider modality coverage.
• Broad shows like BIO are still worth attending for relationship-building and general deal flow, but the manufacturing- and modality-specific shows above tend to generate more directly relevant pipeline for a CDMO.

Prioritization and outreach cadence

Apply the fit-then-readiness model from how to prioritize accounts with modality treated as close to a hard gate rather than a scored attribute: a strong readiness signal at a company outside your modality should not pull it onto the working list. Within modality-qualified accounts, weight phase transitions, approaching regulatory milestones, and CMC or manufacturing executive hiring most heavily, since these correlate most directly with an active or upcoming vendor decision.

Because manufacturing sales cycles and tech-transfer lead times both run long, a CDMO generally benefits from engaging earlier than a CRO or tools vendor would on the same signal, a phase transition or a Fast Track designation is often the right moment to start a conversation, well before the client is ready to commit, precisely because securing future capacity is itself part of the value being sold. Treat a client building its own facility as a prompt to investigate, not an automatic deprioritization: it may be insourcing, or it may be scaling faster than that facility alone can support.